With offices in France (Paris) and in the USA (Princeton, New Jersey), STENTYS became listed on the Paris EuroNext stock exchange (STNT.PA) in October 2010. STENTYS® received CE-Marking for its BMS and DES(P) stents in early 2010 and currently sells its products in more than 8 European countries.
The STENTYS Clinical Program includes both randomised trials and real-life registries, evaluating the STENTYS stent in STEMI with the APPOSITION program, and in bifurcations with the OPEN program. STENTYS has started a 3,000 patient post-market registry in 2012 to examine the real-world use of the STENTYS stent where stent sizing is a concern.
Market capitalization (22-Mar-2017)
Closing share price (22-Mar-2017)